NEW PODCAST!

The NASH Tsunami In Diabetes

Getting Ahead of the Rising Tide in Fatty Liver Disease

Recent prospective studies suggest that more than half of patients with Type 2 diabetes have concomitant NAFLD and more than one in three have NASH.

Other recent research tells us that patients with both diseases are at significantly increased risk of heart disease and cancer and are likely to have lower quality-of-life scores when compared to patients with T2D alone.

Join endocrinologist Kenneth Cusi, MD, forecaster/podcaster Roger Green, and their renowned guests to focus on the scale of the problem (HINT: large and scary!) and practical things you can do today to diagnose and treat these patients more effectively.

new podcast!! ⤵

S3-E1.2 - NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S3-E34 - #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

S3-E34 – #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

Michelle Long and Mazen Noureddin join the Surfers (including Stephen Harrison) for a wrap-up of the major stories of #ILC2022. Much of the episode focuses on NASH Drug Development, with side conversations about the value and challenges of relying on FIB-4 or, even worse, ALT in patient screening and diagnosis.

SurfingNASH.Com is honored to have the following sponsors

Would you like to participate ask a question join the surfers in our next episode?

S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that reported, in a prospective random sample of 835 people with a median age of 55, NAFLD prevalence as being 37%, NASH as being 14% and advanced fibrosis as being 6% in a random asymptomatic patients. Among patient with Type 2 Diabetes, NAFLD prevalence was 70% and NASH was 35%.

S3-E30.4 – Highlighting Intriguing ILC2022 Abstracts: Potential Uses of FIB-4

Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at #ILC2022. This conversation focuses largely on OS025 Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and/or type 2 diabetes in the UK: a longitudinal cohort study.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.
Previous
Next

NASH & Diabetes Podcast and NASH Tsunami Podcast